Deutsche Bank raised the firm’s price target on Praxis Precision (PRAX) to $280 from $65 and keeps a Buy rating on the shares. The company reported a “surprise win” for ulixacaltamide in essential tremor, the analyst tells investors in a research note. The firm remains a buyer of the stock after yesterday’s big rally on its potential in epilepsy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision price target raised to $330 from $80 at Chardan
- Why This Biotech Stock Exploded 184% to a Three-Year High
- Closing Bell Movers: CSX gains over 2% on earnings beat; OZK slips on miss
- Praxis Precision $400M Spot Secondary; price range $152.00-$157.00
- Praxis $400M share sale said to be priced between $152-$157, Bloomberg says